Here is Why West Pharmaceutical Services, Inc. (WST) is Strongly Favored by Hedge Funds

West Pharmaceutical Services, Inc. (NYSE:WST) is one of the 10 best life sciences stocks to buy according to hedge funds.

On February 17, the governing body of West Pharmaceutical Services, Inc. (NYSE:WST) approved a new share repurchase program authorizing the buyback of up to $1 billion of its common stock. The firm highlighted that the previous repurchase program had been fully utilized ahead of its December 31, 2025, expiration. The new authorization reflects continued capital return initiatives and provides the company with added flexibility to repurchase shares.

On February 13, BofA analyst Michael Ryskin reduced his price target on West Pharmaceutical Services, Inc. (NYSE:WST) from $370 to $300, yielding a revised upside potential of more than 24%. The analyst maintained his Buy rating on the shares.

Ryskin highlighted the company’s strong finish to the year and noted that the FY26 outlook came in ahead of consensus, supported by faster expansion in non-GLP-1 high-value products. Following the earnings report and updated outlook, BofA revised its model. However, the firm applied a more conservative valuation multiple, citing broader sector multiple compression.

West Pharmaceutical Services, Inc. (NYSE:WST) specializes in designing and manufacturing integrated containment and delivery systems for healthcare products and injectable drugs. The company has a presence across 50 countries worldwide, offering seals, stoppers, syringes, cartridge components, and self-injection devices. It also delivers other services such as analytical lab services, pre-approval primary packaging support, regulatory expertise, and after-sales support.

While we acknowledge the potential of WST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. Follow Insider Monkey on Google News.